Literature DB >> 9148

Studies on cyclic nucleotides in cancer. I. Adenylate guanylate cyclase and protein kinases in the prostatic sarcoma tissue.

S Shima, Y Kawashima, M Hirai, H Kouyama.   

Abstract

Adenylate, guanylate cyclase and protein kinases in a fibrous sarcoma originating from rat prostate have been studied. A decrease in levels of adenosine 3', 5'-monophosphate (cyclic AMP) and adenylate cyclase activities and an increase in levels of guanosine 3',5'-monophosphate (cyclic GMP) and guanylate cyclase activities were observed in the tumor tissue when compared with the normal prostatic tissue of rats. Protein kinases from the tumor and the prostate were both responsive to exogenous cyclic AMP, with an apparent Ka of 0.08 muM in the tumor and of 0.11 muM in the prostate. It is of interest that the protein kinases from the tumor responded to cyclic AMP to the same extent as was observed in the enzyme preparation from the prostate. The protein kinase from the tumor was more sensitive to cyclic GMP than that from the prostate, showing an apparent Ka of 0.88 muM in the tumor and of 4.85 muM in the prostate. This tumor has been characterized with an increase in guanylate cyclase activities with a subsequent rise in cellular cyclic GMP and an increased sensitivity of the protein kinase to cyclic GMP.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 9148     DOI: 10.1016/0304-4165(76)90401-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Prostaglandin E2 and cyclic AMP levels in human breast tumors.

Authors:  N Feller; T Malachi; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

2.  Changes in mouse skin cyclic nucleotides during chemical carcinogenesis and tumor response to treatment with BCG, L-Dopa and cyclic DBAMP.

Authors:  E Busse; H Rose; K H Riessbeck
Journal:  J Cancer Res Clin Oncol       Date:  1979-06-08       Impact factor: 4.553

3.  Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment.

Authors:  G A Turner; R D Ellis; D Guthrie; A L Latner; J M Monaghan; W M Ross; A W Skillen; R G Wilson
Journal:  J Clin Pathol       Date:  1982-08       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.